Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright

Harmony Biosciences (NASDAQ:HRMY)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $55.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 94.28% from the company’s previous close.

Several other analysts also recently issued reports on HRMY. Mizuho set a $50.00 price objective on Harmony Biosciences in a report on Thursday, February 19th. Bank of America dropped their target price on shares of Harmony Biosciences from $32.00 to $28.00 and set an “underperform” rating on the stock in a research report on Wednesday. Zacks Research upgraded shares of Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. Needham & Company LLC decreased their price objective on shares of Harmony Biosciences from $46.00 to $44.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Harmony Biosciences has an average rating of “Moderate Buy” and a consensus price target of $43.78.

Harmony Biosciences Price Performance

Shares of NASDAQ:HRMY traded up $0.12 on Wednesday, reaching $28.31. 560,237 shares of the company traded hands, compared to its average volume of 937,542. The stock has a market capitalization of $1.63 billion, a PE ratio of 8.90, a P/E/G ratio of 0.25 and a beta of 0.84. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72. The company’s 50 day moving average is $36.57 and its 200-day moving average is $34.19. Harmony Biosciences has a fifty-two week low of $25.52 and a fifty-two week high of $40.87.

Harmony Biosciences (NASDAQ:HRMY) last announced its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 24.88% and a net margin of 22.50%.The company had revenue of $243.78 million for the quarter, compared to analyst estimates of $240.04 million. During the same period last year, the firm earned $0.85 earnings per share. The firm’s revenue for the quarter was up 21.1% on a year-over-year basis. As a group, analysts anticipate that Harmony Biosciences will post 2.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Sandip Kapadia sold 20,961 shares of Harmony Biosciences stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $35.92, for a total transaction of $752,919.12. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 50,640 shares of company stock worth $1,932,256 over the last ninety days. 23.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HRMY. Amundi raised its position in Harmony Biosciences by 115.6% during the first quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after acquiring an additional 21,266 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Harmony Biosciences by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after buying an additional 984 shares during the last quarter. Empowered Funds LLC acquired a new stake in shares of Harmony Biosciences in the first quarter worth $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Harmony Biosciences by 53.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock worth $3,166,000 after acquiring an additional 33,058 shares during the period. Finally, AlphaQuest LLC increased its position in Harmony Biosciences by 340.2% during the second quarter. AlphaQuest LLC now owns 17,601 shares of the company’s stock worth $556,000 after acquiring an additional 13,603 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Harmony Biosciences News Roundup

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Company reported 21% YoY product revenue growth and reiterated FY2026 net‑revenue guidance of about $1.0 billion, signaling continued commercial momentum for WAKIX. Business Wire: Strong 2025 Results
• Positive Sentiment: Needham trimmed its price target from $46 to $44 but maintained a “buy” rating, implying substantial upside vs. the current share price and showing at least one analyst remains constructive. Benzinga: Needham PT Change
• Neutral Sentiment: Company published its Q4 earnings materials and an earnings‑call transcript/slides, which investors can review for management detail on margin dynamics, commercialization trends, and pipeline priorities. Press Release / Slide Deck Earnings Call Transcript
• Negative Sentiment: Q4 EPS came in at $0.38 vs. consensus ~$0.84 (and vs. $0.85 a year ago), a large earnings miss that explains near‑term selling pressure despite the revenue beat. Zacks: Q4 Earnings Miss
• Negative Sentiment: Bank of America cut its price target to $28 and moved to “underperform” — a downgrading voice that increases near‑term downside risk. Benzinga: BofA PT Cut
• Negative Sentiment: Truist lowered its rating to Hold, adding to mixed analyst sentiment and reducing consensus conviction. American Banking News: Truist Rating Lowered
• Negative Sentiment: Outlets are flagging ongoing legal and generic‑competition risks for WAKIX that could pressure long‑term revenue visibility if adverse outcomes occur. Yahoo Finance: Legal & Generic Risks

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.